Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | FCER2 | P06734 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703226 | 0.84 | HTR2A (0.49) | HTR2AHTR2CHTR2BACEMME | |
| SCHEMBL1705759 | 0.84 | HTR2A (0.49) | HTR2AHTR2CHTR2BACEMME | |
| SCHEMBL12191628 | 0.83 | MME (0.55) | HTR2AHTR2CHTR2BACEMME | |
| SCHEMBL1709316 | 0.82 | HTR2A (0.50) | HTR2AHTR2CHTR2BACEMME | |
| SCHEMBL1709349 | 0.82 | HTR2A (0.50) | HTR2AHTR2CHTR2BACEMME | |
| SCHEMBL1709341 | 0.81 | CYP1A2 (0.60) | CPA1CYP1A2 | |
| SCHEMBL16724762 | 0.81 | HTR2A (0.57) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL7324604 | 0.81 | MME (0.50) | HTR2AHTR2CHTR2BACEMME | |
| SCHEMBL8872177 | 0.79 | CYP1A2 (0.62) | HTR2AHTR2CHTR2BACEMME | |
| SCHEMBL12827325 | 0.79 | MME (0.49) | HTR2AHTR2CHTR2BACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | HTR2A 3026/4885HTR2C 3558/4885HTR2B 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.